Company Overview of InnaVirVax SAS
InnaVirVax SAS operates as a biopharmaceutical company. It develops therapeutic vaccines and biotherapy for HIV infection, and prognostic tests for predicting the rate of progression towards AIDS in HIV-infected asymptomatic patients, as well as develops cancer biotherapy products. The company was incorporated in 2008 and is based in Evry, France.
Genopole Entreprises - CAMPUS 1
4 rue Pierre Fontaine
Founded in 2008
33 1 80 85 60 83
33 1 80 85 60 87
Key Executives for InnaVirVax SAS
InnaVirVax SAS Key Developments
Similar Private Companies By Industry
|A.T.O. ZIZINE S.A.S||Europe|
|Advicenne Pharma SA||Europe|
|Aguettant Santé S.A.||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact InnaVirVax SAS, please visit www.innavirvax.fr. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.